| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.3 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.3 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.3 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.068 | 0.4 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.075 | 0.4 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |